As of 2026-03-07, the Intrinsic Value of Arcutis Biotherapeutics Inc (ARQT) is 43.03 USD. This Arcutis valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 24.00 USD, the upside of Arcutis Biotherapeutics Inc is 79.30%.
The range of the Intrinsic Value is 34.55 - 53.91 USD
Based on its market price of 24.00 USD and our intrinsic valuation, Arcutis Biotherapeutics Inc (ARQT) is undervalued by 79.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (142.90) - (34.63) | (52.50) | -318.8% |
| DCF (Growth 10y) | (17.44) - (41.84) | (21.58) | -189.9% |
| DCF (EBITDA 5y) | 34.55 - 53.91 | 43.03 | 79.3% |
| DCF (EBITDA 10y) | 33.46 - 59.15 | 44.49 | 85.4% |
| Fair Value | -1.26 - -1.26 | -1.26 | -105.26% |
| P/E | (2.89) - (3.59) | (3.23) | -113.5% |
| EV/EBITDA | (0.84) - 26.24 | 11.17 | -53.4% |
| EPV | (14.08) - (18.57) | (16.33) | -168.0% |
| DDM - Stable | (1.93) - (12.60) | (7.26) | -130.3% |
| DDM - Multi | (1.17) - (5.96) | (1.96) | -108.1% |
| Market Cap (mil) | 2,939.76 |
| Beta | 0.38 |
| Outstanding shares (mil) | 122.49 |
| Enterprise Value (mil) | 3,005.81 |
| Market risk premium | 4.60% |
| Cost of Equity | 6.86% |
| Cost of Debt | 9.87% |
| WACC | 6.97% |